The U.S. Drug Enforcement Administration's decision to forward a petition to reschedule psilocybin to the U.S. Department of Health and Human Services for scientific review represents a significant regulatory milestone in the decades-long effort to integrate psychedelics into mainstream medicine. Psylutions, Colorado's first licensed regulated cultivator and manufacturer of psilocybin, has welcomed this development as a crucial step toward aligning policy with scientific evidence.
Rhonda DeSantis, founder of Psylutions, stated that this move reflects long-overdue alignment between policy and science and brings healing one step closer to those who need it most. The company, through its licensed cultivation, precision dosing, and partnership network, is preparing to help build a future where psilocybin therapy is safe, regulated, and accessible. If psilocybin is moved from Schedule I to Schedule II of the Controlled Substances Act, patients in palliative care and veterans suffering from PTSD would be among the first to benefit through expanded pathways like Right to Try.
Henry Baskerville, General Counsel and Partner at Psylutions, described this development as signaling a regulatory awakening, noting that as agencies begin engaging with medical evidence over stigma, the industry is entering a watershed moment for psychedelics. He emphasized that psychedelics hold even greater potential for significant medical applications than cannabis and stressed the importance of approaching this transition with the highest standards. Psylutions has invested heavily in infrastructure to meet these standards, including strain optimization, lab-verified dosing, and triple HEPA filtration systems to mitigate contamination risk.
The company already partners with over 50% of healing centers operating across Colorado to provide regulated psilocybin solutions for chronic pain, trauma relief, end-of-life care, and broader mental wellness. Rescheduling would accelerate research opportunities and expand access for clinicians and licensed healing centers, potentially transforming mental health treatment options nationwide. DeSantis added that as soon as psilocybin is rescheduled from Schedule I, patients facing terminal illness and veterans at risk of suicide will finally have safe, legal access through Right to Try, with Psylutions committed to ensuring that access is built on medicine that is effective, rigorously verified, and responsibly produced. Learn more at https://ThePsylutions.com.
